Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort

Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, r...

Full description

Saved in:

Bibliographic Details
Published in:	Current oncology (Toronto) Vol. 31; no. 3; pp. 1656 - 1666
Main Authors:	Nannini, Simon, Guisier, Florian, Curcio, Hubert, Ricordel, Charles, Demontrond, Pierre, Abdallahoui, Safa, Baloglu, Seyyid, Greillier, Laurent, Chouaid, Christos, Schott, Roland
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 01.03.2024 MDPI
Subjects:	Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological - therapeutic use Brain brain metastasis Brain Neoplasms Carcinoma, Non-Small-Cell Lung - drug therapy Care and treatment central nervous system Development and progression Humans immunotherapy Lung cancer, Non-small cell Lung cancer, Small cell Lung Neoplasms - drug therapy Metastasis non-small cell lung cancer Patient outcomes Pharmaceutical industry Radiotherapy real-life data Retrospective Studies France United States non-small cell lung cancer brain metastasis real-life data immunotherapy central nervous system
ISSN:	1718-7729, 1198-0052, 1718-7729
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!